AZTR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 22:59):

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases...

Stats
Šios dienos apimtis	11.71M
Vidutinė apimtis	927 342
Rinkos kapitalizacija	5.24M
EPS	$0 ( 2024-03-12 )
Kita pelno data	( $0 ) 2024-06-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.00200 (1.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Staskey Norm	Buy	47 600	Common Stock
2024-02-13	Whitfill Travis	Buy	15 000	Common Stock
2024-02-13	Staskey Norm	Buy	3 300	Common Stock
2024-02-13	Salva Francisco D.	Buy	333 300	Common Stock
2023-09-08	Staskey Norm	Buy	10 000	Stock Options (Right To Buy)

INSIDER POWER
44.35
Last 69 transactions
Buy: 15 407 806 \| Sell: 6 059 394

Tūris Koreliacija

Ilgas: -0.15 (neutral)

Trumpas: -0.36 (neutral)

Signal:(41.701) Neutral

Azitra, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Azitra, Inc. Koreliacija - Valiuta/Žaliavos

-0.62
( weak negative )

-0.70
( moderate negative )

0.00
( neutral )

0.49
( neutral )

Azitra, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$686 000
Bruto pelnas:	$686 000 (100.00 %)
EPS:	$-1.630

FY	2023
Pajamos:	$686 000
Bruto pelnas:	$686 000 (100.00 %)
EPS:	$-1.630

FY	2022
Pajamos:	$284 000
Bruto pelnas:	$284 000 (100.00 %)
EPS:	$-0.880

Financial Reports:

No articles found.

Azitra, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Azitra, Inc.

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.